Natibo (Risperidone)

Risperidone blocks dopamine D2 receptors, decreasing excessive dopaminergic activity that contributes to psychosis. It also antagonizes serotonin 5‑HT2A receptors, which helps balance mood and reduces negative symptoms. This dual receptor blockade results in antipsychotic, mood‑stabilising, and anti‑irritability effects across its approved indications.

The dose of Natibo is individualized by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, age, renal function and other medical factors. Healthcare providers start with a low dose and titrate as needed, following local prescribing guidelines and therapeutic response.

Safety data for risperidone in pregnancy and lactation are limited. The drug is classified as pregnancy category unknown, and it passes into breast milk. Prescribers must weigh potential benefits against possible risks to the fetus or infant and consider alternative therapies when appropriate.

To request Natibo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and assistance with import documentation.

Compared with other atypical agents, risperidone offers a relatively strong D2 antagonism combined with 5‑HT2A blockade, providing robust control of positive psychotic symptoms while also addressing mood disturbances. Its side‑effect profile includes a higher propensity for prolactin elevation but lower metabolic weight gain than some newer agents such as olanzapine.

Natibo should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Natibo is taken orally. The tablet (or other oral form) should be swallowed whole with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable blood levels.

The most serious adverse reactions include tardive dyskinesia, a potentially irreversible movement disorder; neuroleptic malignant syndrome, a life‑threatening condition marked by fever and rigidity; and metabolic complications such as significant weight gain, hyperglycaemia and dyslipidaemia. Patients should be monitored regularly for early signs of these events.

Natibo is contraindicated in individuals with known hypersensitivity to risperidone or any excipients in the formulation. It should also be avoided in patients with severe central nervous system depression, uncontrolled cardiovascular disease, or those taking medications that may cause dangerous additive effects without proper monitoring.